Skip to main content

Advertisement

Table 2 Clinician-reported participant characteristics

From: Content validity and ePRO usability of the BPI-sf and “worst pain” item with pleural and peritoneal mesothelioma

Clinical characteristics Overall N = 21a Pleural N = 18 Peritoneal N = 4
Years since mesothelioma diagnosis
 Mean (SD) 1.2 (1.5) 1.1 (1.5) 1.4 (1.9)
 Range (Min, Max) (0.1, 4.8) (0.1, 4.8) (0.2, 4.2)
Stage of mesothelioma, n (%)b
 Stage I/Stage II 3 (14.3%) 3 (16.7%) 0 (0%)
 Stage III/Stage IV 17 (80.9%) 14 (77.8%) 4 (100%)
RECIST criteria, n (%)d
 Partial response (PR) 4 (19.0%) 2 (11.1%) 2 (50.0%)
 Progressive disease (PD) 4 (19.0%) 4 (22.2%) 0 (0%)
 Stable disease (SD) 10 (47.6%) 9 (50.0%) 2 (50.0%)
ECOG performance status grade
 Grade 0: Fully active 8 (38.1%) 7 (38.9%) 2 (50.0%)
 Grade 1: Restricted, light work only 13 (61.9%) 11 (61.1%) 2 (50.0%)
Comorbiditiesc
 Asthma 3 (14.3%) 3 (16.7%) 1 (25.0%)
 Anxiety/depression 2 (9.5%) 1 (5.6%) 1 (25.0%)
 Arthritis 2 (9.5%) 2 (11.1%) 0 (0%)
 Other cancere 10 (47.6%) 9 (50.0%) 1 (25.0%)
 Diabetes 2 (9.5%) 2 (11.1%) 0 (0%)
 Hypertension (high blood pressure) 12 (57.1%) 12 (66.7%) 0 (0%)
 Chest pain/abdominal pain 3 (14.3%) 2 (11.1%) 1 (25.0%)
 Otherf 6 (28.6%) 5 (27.8%) 1 (25.0%)
 None 1 (4.8%) 1 (5.6%) 0 (0%)
Current medicationsb
 Chemotherapy or other cancer treatment 18 (85.7%) 16 (88.9%) 3 (75.0%)
 Nutritional support 9 (42.9%) 8 (44.4%) 1 (25.0%)
 Pain medications/corticosteroids 11 (52.4%) 9 (50.0%) 3 (75.0%)
 Otherg 4 (19.0%) 3 (16.7%) 1 (25.0%)
  1. aOne patient had pleural and peritoneal disease and is included in both disease-specific columns
  2. bOne pleural participant with “unknown” status
  3. cNot mutually exclusive
  4. dThree pleural participants with “unknown” RECIST criteria
  5. eAs a requirement for study eligibility the participants had to be currently disease-free from other invasive malignancy and recovered from any toxicity related to previous or current anticancer therapies for other cancer
  6. fFor pleural participants: one participant reported having “GERD, gastroparesis, hyperlipidemia”; one participant reported having “allergies, hyperparathyroidism, GERD”; one participant reported having “chronic kidney disease”; one participant reported Congestive heart failure/Heart disease; one participant reported “COPD.” The one peritoneal participant reported having “anemia”
  7. gOther = Correction of metabolic syndrome disorder (n = 3; 2 pleural, 1 peritoneal). Antibiotics (n = 1 pleural)